Green Cross Holdings Corporation operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Green Cross Holdings with three other
pharmaceutical manufacturers in Asia:
Hisamitsu Pharmaceutical Co Inc
sales of 147.87 billion Japanese Yen [US$1.32 billion]
of which 100%
(1.52 trillion Korean Won [US$1.34 billion]
of which 55%
was Merchandise), and
China Resources Double-Crane Pharmaceutical Company Limited
based in China
(8.22 billion Chinese Renmimbi [US$1.23 billion]
of which 66%
was Non- transfusion).
Green Cross Holdings reported sales of 1.55 trillion Korean Won (US$1.36 billion)
December of 2018.
increase of 5.7%
versus 2017, when the company's sales were 1.46 trillion Korean Won.
Sales at Green Cross Holdings have increased during each of the previous five years
(and since 2013, sales have increased a total of 66%).